These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38384494)

  • 1. Budget Impact of the Oncotype DX Breast Recurrence Score
    Lux MP; Minartz C; Müller-Huesmann H; Sandor MF; Radeck-Knorre S; Neubauer AS
    Breast Care (Basel); 2024 Feb; 19(1):27-33. PubMed ID: 38384494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The budget impact of utilizing the Oncotype DX Breast Recurrence Score test from a US healthcare payer perspective.
    Berdunov V; Laws E; Cuyun Carter G; Luo R; Russell C; Campbell S; Force J; Abdou Y
    J Med Econ; 2023; 26(1):973-990. PubMed ID: 37466220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cost-consequence model of using the 21-gene assay to identify patients with early-stage node-positive breast cancer who benefit from adjuvant chemotherapy in the Netherlands.
    Simons MJHG; Machielsen PM; Spoorendonk JA; Ignacio T; Drost PB; Jacobs T; de Jongh FE
    J Med Econ; 2024; 27(1):445-454. PubMed ID: 38436289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irish national real-world analysis of the clinical and economic impact of 21-gene oncotype DX® testing in early-stage, 1-3 lymph node-positive, oestrogen receptor-positive, HER2-negative, breast cancer.
    Browne IM; McLaughlin RA; Weadick CS; O'Sullivan S; McSorley LM; Hadi DK; Millen SJ; Higgins MJ; Crown JP; Prichard RS; McCartan DP; Hill AD; Connolly RM; Noonan SA; O'Mahony D; Murray C; O'Hanlon-Brown C; Hennessy BT; Quinn CM; Kelly CM; O'Reilly S; Morris PG; Walshe JM
    Breast Cancer Res Treat; 2024 Oct; ():. PubMed ID: 39365509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Budget impact analysis of gene expression tests to aid therapy decisions for breast cancer patients in Germany.
    Lux MP; Nabieva N; Hildebrandt T; Rebscher H; Kümmel S; Blohmer JU; Schrauder MG
    Breast; 2018 Feb; 37():89-98. PubMed ID: 29128582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score test in node-positive early breast cancer.
    Berdunov V; Millen S; Paramore A; Hall P; Perren T; Brown R; Griffin J; Reynia S; Fryer N; Longworth L
    J Med Econ; 2022; 25(1):591-604. PubMed ID: 35416089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Budget impact of the Oncotype DX® test compared to other gene expression tests in patients with early breast cancer in Germany.
    Lux MP; Minartz C; Müller-Huesmann H; Sandor MF; Herrmann KH; Radeck-Knorre S; Neubauer AS
    Cancer Treat Res Commun; 2022; 31():100519. PubMed ID: 35093682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recommendations from the EGAPP Working Group: does the use of Oncotype DX tumor gene expression profiling to guide treatment decisions improve outcomes in patients with breast cancer?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group*
    Genet Med; 2016 Aug; 18(8):770-9. PubMed ID: 26681310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis.
    Harnan S; Tappenden P; Cooper K; Stevens J; Bessey A; Rafia R; Ward S; Wong R; Stein RC; Brown J
    Health Technol Assess; 2019 Jun; 23(30):1-328. PubMed ID: 31264581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost and Clinical Benefits Associated with Oncotype DX® Test in Patients with Early-Stage HR+/HER2- Node-Negative Breast Cancer in the Netherlands.
    de Jongh FE; Efe R; Herrmann KH; Spoorendonk JA
    Int J Breast Cancer; 2022; 2022():5909724. PubMed ID: 36250028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score
    Berdunov V; Cuyun Carter G; Laws E; Luo R; Russell CA; Campbell S; Abdou Y; Force J
    Clinicoecon Outcomes Res; 2024; 16():471-482. PubMed ID: 38855430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer.
    Hall PS; McCabe C; Stein RC; Cameron D
    J Natl Cancer Inst; 2012 Jan; 104(1):56-66. PubMed ID: 22138097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in a Middle-Income Country, Turkey: Results of a Prospective Multicenter Study.
    Özmen V; Çakar B; Gökmen E; Özdoğan M; Güler N; Uras C; Ok E; Demircan O; Işıkdoğan A; Saip P
    Eur J Breast Health; 2019 Jul; 15(3):183-190. PubMed ID: 31312795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients.
    Stemmer SM; Klang SH; Ben-Baruch N; Geffen DB; Steiner M; Soussan-Gutman L; Merling S; Svedman C; Rizel S; Lieberman N
    Breast Cancer Res Treat; 2013 Jul; 140(1):83-92. PubMed ID: 23801158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database.
    Roberts MC; Miller DP; Shak S; Petkov VI
    Breast Cancer Res Treat; 2017 Jun; 163(2):303-310. PubMed ID: 28243896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: Real world experience in Greater Manchester, UK.
    Loncaster J; Armstrong A; Howell S; Wilson G; Welch R; Chittalia A; Valentine WJ; Bundred NJ
    Eur J Surg Oncol; 2017 May; 43(5):931-937. PubMed ID: 28111076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting Chemotherapy Benefit across Different Races in Early-Stage Breast Cancer Patients Using the Oncotype DX Score.
    Shaw VR; Amos CI; Cheng C
    Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score
    Berdunov V; Millen S; Paramore A; Griffin J; Reynia S; Fryer N; Brown R; Longworth L
    Clinicoecon Outcomes Res; 2022; 14():619-633. PubMed ID: 36157054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Oncotype DX on treatment decisions in ER-positive, node-negative breast cancer with histologic correlation.
    Biroschak JR; Schwartz GF; Palazzo JP; Toll AD; Brill KL; Jaslow RJ; Lee SY
    Breast J; 2013; 19(3):269-75. PubMed ID: 23614365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.